NEKTAR THERAPEUTICS 4

Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, had 16,500 stock options vest into the right to acquire common stock at a $15.15 exercise price.

On July 24, 2026, Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, had 16,500 stock options with a $15.15 exercise price vest into the right to acquire common stock at $0.00 cost upon satisfaction of a performance-based vesting condition under the company’s 2017 Amended and Restated Performance Incentive Plan; these options were originally granted on December 13, 2024 with both performance- and time-based vesting, and the issuer’s Organization and Compensation Committee determined on July 23, 2026 that the performance criteria had been met, triggering vesting (subject to continued time-based vesting), resulting in post-transaction beneficial ownership of 16,500 derivative securities.

Filing Facts

CIK

906709

Ticker

NKTR

Form

4

Source Type

fda

Accession

0001193125-26-316458

Alert Tier

5